Topical paromomycin with or without gentamicin for cutaneous leishmaniasis

Autor: Diane Ullman, Aicha Boukthir, Nabil Belhadj Hamida, Ryan C. Adams, Kirsten S. Smith, Mourad Mokni, Jihene Bettaieb, Zaher El Ahmadi, Philip L. Smith, Adel Gharbi, Robert M. Rice, George D. Thorne, Nissaf Ben Alaya, A. Zaatour, Carl J. Nielsen, Jeanne A. Norwood, Max Grogl, Hechmi Louzir, Sadok Chlif, Gloria Morizot, William F. McCarthy, Alan J. Magill, Afif Ben Salah, Mara Kreishman-Deitrick, Karen M. Kopydlowski, Janet Ransom, Judith Berman, Pierre Buffet, Nathalie Ben Messaoud, Kidar Abdelhamid, Evelyn Guedri, Douglas B. Tang

Publikováno v: New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2013, 368 (6), pp.524-32. ⟨10.1056/NEJMoa1202657⟩
New England Journal of Medicine, 2013, 368 (6), pp.524-32. ⟨10.1056/NEJMoa1202657⟩

International audience; BACKGROUND: There is a need for a simple and efficacious treatment for cutaneous leishmaniasis with an acceptable side-effect profile. METHODS: We conducted a randomized, vehicle-controlled phase 3 trial of topical treatments

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7048bbfb40ab6d667daf8f05bd432e4
https://hal-riip.archives-ouvertes.fr/pasteur-00793585/file/Topical_Paromomycin_with_or_without_Gentamicin_for_Cutaneous_Leishmaniasis.pdf